Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

9 enrolled 10 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04331067 2025-04-23

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Phase 1/2 Active not recruiting

15 enrolled 12 charts

Breast

Triple Negative Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

Phase 3 Active not recruiting

808 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06637306 2025-03-26

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Phase EARLY_PHASE1 Recruiting

15 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Phase 2 Recruiting

23 enrolled

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02423603 2025-03-10

PAKT

Phase 2 Completed

71 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05498896 2025-03-10

BARBICAN

Phase 2 Active not recruiting

146 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05020860 2025-02-27

RESPONSE

Phase 2 Recruiting

185 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06795503 2025-01-28

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

Phase 3 Not yet recruiting

1,462 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

129 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

57 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02938442 2024-11-07

Vaccination of Triple Negative Breast Cancer Patients

Phase 1/2 Completed

16 enrolled 30 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Breast

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02689427 2024-09-19

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

Phase 2 Completed

100 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3 Active not recruiting

782 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06407310 2024-05-09

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Phase 2 Not yet recruiting

25 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

Phase 2 Not yet recruiting

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Breast

Triple Negative Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Phase 2 Unknown

49 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02672475 2023-11-22

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Phase 1 Completed

29 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms